Espindolol

Drug Profile

Espindolol

Alternative Names: AGI-001; S-pindolol - AGI Therapeutics

Latest Information Update: 31 Jul 2015

Price : $50

At a glance

  • Originator AGI Therapeutics
  • Class Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Serotonin 1A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Irritable bowel syndrome; Non-ulcer dyspepsia

Most Recent Events

  • 19 Feb 2007 Discontinued - Phase-II for Non-ulcer dyspepsia in United Kingdom (PO)
  • 19 Feb 2007 Discontinued - Phase-II for Irritable bowel syndrome in Ireland (PO)
  • 03 Oct 2006 Interim results from a phase II clinical trial in patients with irritable bowel syndrome have been added to the adverse events and Digestive System Disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top